SK Biopharmaceuticals Co., Ltd.
326030
Hisse Senetlerindeki Sıralama
#4040
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Hisse Fiyatı
$51.31
Piyasa Değeri
$4.02B
Değişim (1 gün)
-2.62%
Değişim (1 yıl)
-28.88%
Ülke
KR
Ticaret SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
SK Biopharmaceuticals Co., Ltd. (326030) için EPS
June 2026 itibariyle EPS TTM: $3.42
SK Biopharmaceuticals Co., Ltd. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $3.42'dir. 2024 yılı sonunda, şirketin EPS'si $2.09 idi; bu, 2023 yılındaki EPS olan $-0.32 ile önceki yıla göre artış.
SK Biopharmaceuticals Co., Ltd. için 2011 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $3.42 | 52.67% |
| 2025 | $2.24 | 7.31% |
| 2024 | $2.09 | -743.06% |
| 2023 | $-0.32 | -77.01% |
| 2022 | $-1.41 | -302.57% |
| 2021 | $0.70 | -121.93% |
| 2020 | $-3.18 | 233.25% |
| 2019 | $-0.95 | -52.18% |
| 2018 | $-1.99 | 8.75% |
| 2017 | $-1.83 | 264.02% |
| 2016 | $-0.50 | 5.40% |
| 2015 | $-0.48 | -30.23% |
| 2014 | $-0.68 | -29.69% |
| 2013 | $-0.97 | 36.72% |
| 2012 | $-0.71 | 69.47% |
| 2011 | $-0.42 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | 406.48% |
US
|
|
| $-7.98 | -333.35% |
US
|
|
| $-5.29 | -254.69% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 711.18% |
NL
|
